NO343937B1 - Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft - Google Patents

Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft

Info

Publication number
NO343937B1
NO343937B1 NO20071584A NO20071584A NO343937B1 NO 343937 B1 NO343937 B1 NO 343937B1 NO 20071584 A NO20071584 A NO 20071584A NO 20071584 A NO20071584 A NO 20071584A NO 343937 B1 NO343937 B1 NO 343937B1
Authority
NO
Norway
Prior art keywords
pharmaceutically acceptable
solid dispersion
sugar
composition
fluorophenoxy
Prior art date
Application number
NO20071584A
Other languages
English (en)
Norwegian (no)
Other versions
NO20071584L (no
Inventor
Susanne Zuleger
Jacquos Dumas
Paul Ehrlich
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO343937(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of NO20071584L publication Critical patent/NO20071584L/no
Publication of NO343937B1 publication Critical patent/NO343937B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
NO20071584A 2004-08-27 2007-03-26 Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft NO343937B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60475204P 2004-08-27 2004-08-27
PCT/US2005/030541 WO2006026500A1 (en) 2004-08-27 2005-08-29 New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders

Publications (2)

Publication Number Publication Date
NO20071584L NO20071584L (no) 2007-05-24
NO343937B1 true NO343937B1 (no) 2019-07-15

Family

ID=35517032

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20071584A NO343937B1 (no) 2004-08-27 2007-03-26 Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft
NO2019033C NO2019033I1 (no) 2004-08-27 2019-08-05 regorafenib

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2019033C NO2019033I1 (no) 2004-08-27 2019-08-05 regorafenib

Country Status (41)

Country Link
US (2) US20060058358A1 (https=)
EP (2) EP2589384A1 (https=)
JP (1) JP5017115B2 (https=)
KR (1) KR101336737B1 (https=)
CN (2) CN102885813A (https=)
AR (1) AR050616A1 (https=)
AU (1) AU2005279996A1 (https=)
BR (1) BRPI0514715B1 (https=)
CA (1) CA2578438C (https=)
CL (1) CL2010001484A1 (https=)
CR (1) CR8980A (https=)
CY (1) CY2017038I1 (https=)
DK (1) DK1793824T3 (https=)
EA (1) EA010832B1 (https=)
EC (1) ECSP077299A (https=)
ES (1) ES2561618T3 (https=)
GT (1) GT200500230A (https=)
HN (1) HN2005000484A (https=)
HR (1) HRP20160156T1 (https=)
HU (2) HUE026654T2 (https=)
IL (1) IL181590A (https=)
LT (1) LTC1793824I2 (https=)
LU (1) LUC00047I2 (https=)
MA (1) MA28911B1 (https=)
ME (2) MEP35808A (https=)
MX (1) MX2007002397A (https=)
MY (1) MY191349A (https=)
NI (1) NI200700064A (https=)
NO (2) NO343937B1 (https=)
NZ (1) NZ553557A (https=)
PE (2) PE20100432A1 (https=)
PL (1) PL1793824T3 (https=)
PT (1) PT1793824E (https=)
RS (1) RS54580B1 (https=)
SI (1) SI1793824T1 (https=)
TN (1) TNSN07076A1 (https=)
TW (1) TWI369987B (https=)
UA (1) UA92472C2 (https=)
UY (1) UY29086A1 (https=)
WO (1) WO2006026500A1 (https=)
ZA (1) ZA200702392B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) * 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
KR101381454B1 (ko) * 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
SG160364A1 (en) * 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20080026038A1 (en) * 2006-07-26 2008-01-31 Remington Direct Lp No laxation, low flatulence bulking system
US20090074917A2 (en) * 2006-07-26 2009-03-19 Remington Direct Lp Low-calorie, no laxation bulking system
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
AU2007316558A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
CN101702878B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 可溶性差的药物的药物组合物
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010068951A1 (en) * 2008-12-12 2010-06-17 Fox Chase Cancer Center Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
TW201202234A (en) * 2010-06-09 2012-01-16 Abbott Lab Solid dispersions containing kinase inhibitors
ES2801678T3 (es) 2010-07-12 2021-01-12 Salix Pharmaceuticals Inc Formulaciones de rifaximina y sus usos
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MA34553B1 (fr) 2010-10-01 2013-09-02 Bayer Ip Gmbh Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
US9518020B2 (en) 2013-10-04 2016-12-13 Hetero Research Foundation Process for Regorafenib
CN104721142B (zh) * 2013-12-18 2020-04-28 山东新时代药业有限公司 一种利伐沙班固体分散体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
CN111166724A (zh) * 2018-11-09 2020-05-19 北京化工大学 一种瑞戈非尼纳米分散体、片剂及其制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
EP4114359A1 (en) * 2020-03-05 2023-01-11 Aurigene Discovery Technologies Limited Pharmaceutical compositions of a kinase inhibitor
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN112842998A (zh) * 2021-01-19 2021-05-28 深圳市简一生物科技有限公司 一种瑞戈非尼分散剂及其制备方法
FR3123358B1 (fr) 2021-05-25 2024-05-10 Vecormat Bfc Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle.
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
CN114767633B (zh) * 2022-04-07 2023-03-31 郑州大学第一附属医院 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US4220302A (en) 1978-07-21 1980-09-02 Hampton Diane M Nursing bottle holder
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
BR9814375A (pt) * 1997-12-22 2002-05-21 Bayer Ag Inibição de raf cinase usando difenil uréias substituìdas simétricas e assimétricas
ID26328A (id) * 1997-12-22 2000-12-14 Bayer Ag Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
SK286213B6 (sk) * 1997-12-22 2008-05-06 Bayer Corporation Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie
CN100522934C (zh) * 1999-01-13 2009-08-05 拜尔有限公司 用ω-羧基芳基取代的二苯脲作为raf激酶抑制剂
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP3789066B2 (ja) 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
CA2407063A1 (en) * 2000-04-19 2001-10-25 Takeo Hirose Solid dispersion with improved absorbability
US8725620B2 (en) 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
EP1308156A4 (en) * 2000-08-11 2009-07-15 Eisai R&D Man Co Ltd AGGREGATE SOLID DISPERSION WITH IMPROVED SOLUBILITY
CA2431319A1 (en) 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL157075A0 (en) * 2001-02-13 2004-02-08 Astrazeneca Ab Novel modified release formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
CA2466762A1 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007428A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
CA2430180C (en) 2003-05-21 2010-03-16 Royal Group Technologies Limited Cascade shade
WO2006026501A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041698A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2005009961A2 (en) * 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
NO20060870L (no) * 2003-07-23 2006-04-07 Bayer Pharmaceuticals Corp Fluorsubstituert omega-karboksyaryldifenylurea for behandling og profylakse av sykdommer og tilstander

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHMAD TANYA ET AL, "Kinase inhibition with BAY 43-9006 in renal cell carcinoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 SEP 2004, Presentation at First International Conference on Innovations and Challenges in Renal Cancer, Cambridge, Massachusetts, (20040319), vol. 10, no. 18 Pt 2, ISSN 1078-0432, pages 6388S - 6392S, , Dated: 01.01.0001 *
LEUNER C ET AL, "Improving drug solubility for oral delivery using solid dispersions", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, (20000703), vol. 50, no. 1, ISSN 0939-6411, pages 47 - 60, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
ME00152B (me) 2010-10-10
JP2008511685A (ja) 2008-04-17
NZ553557A (en) 2010-08-27
GT200500230A (es) 2006-03-28
KR101336737B1 (ko) 2013-12-04
CL2010001484A1 (es) 2011-04-25
JP5017115B2 (ja) 2012-09-05
UY29086A1 (es) 2006-03-31
CN101287463A (zh) 2008-10-15
PL1793824T3 (pl) 2016-06-30
TW200616627A (en) 2006-06-01
PE20060505A1 (es) 2006-06-18
NO2019033I1 (no) 2019-08-05
HUE026654T2 (en) 2016-07-28
LUC00047I2 (https=) 2018-01-10
CY2017038I2 (el) 2018-06-27
HN2005000484A (es) 2010-06-08
WO2006026500A1 (en) 2006-03-09
MY191349A (en) 2022-06-17
BRPI0514715B1 (pt) 2021-11-03
CR8980A (es) 2007-10-22
MX2007002397A (es) 2007-05-15
LTC1793824I2 (lt) 2017-06-12
LUC00047I1 (https=) 2017-11-15
SI1793824T1 (sl) 2016-03-31
EP1793824A1 (en) 2007-06-13
CN102885813A (zh) 2013-01-23
MA28911B1 (fr) 2007-10-01
HUS1700047I1 (hu) 2017-12-28
PT1793824E (pt) 2016-03-11
TWI369987B (en) 2012-08-11
NO20071584L (no) 2007-05-24
PE20100432A1 (es) 2010-07-21
RS54580B1 (sr) 2016-06-30
US20060058358A1 (en) 2006-03-16
EP1793824B1 (en) 2015-11-18
AR050616A1 (es) 2006-11-08
ZA200702392B (en) 2008-11-26
CY2017038I1 (el) 2018-06-27
KR20070067104A (ko) 2007-06-27
EA010832B1 (ru) 2008-12-30
IL181590A0 (en) 2007-07-04
CA2578438C (en) 2015-10-06
ES2561618T3 (es) 2016-02-29
AU2005279996A1 (en) 2006-03-09
EA200700501A1 (ru) 2007-08-31
BRPI0514715A (pt) 2008-06-24
US20170165243A1 (en) 2017-06-15
HRP20160156T1 (hr) 2016-03-11
UA92472C2 (ru) 2010-11-10
NI200700064A (es) 2008-03-03
EP2589384A1 (en) 2013-05-08
DK1793824T3 (en) 2016-02-01
MEP35808A (en) 2010-06-10
CA2578438A1 (en) 2006-03-09
TNSN07076A1 (en) 2008-06-02
IL181590A (en) 2013-04-30
ECSP077299A (es) 2007-04-26

Similar Documents

Publication Publication Date Title
NO343937B1 (no) Sammensetning som omfatter en fast dispersjon av minst 4{4-[3-(4-klor-3-trifluormetylfenyl)-ureido]-3-fluorfenoksy}-pyridin-2-karboksylsyremetylamid i hovedsakelig amorf form, dets solvater, hydrater, farmasøytisk akseptable salter eller en kombinasjon derav og en farmasøytisk akseptabel matriks som omfatter en farmasøytisk akseptabel polymer eller et sukker og/eller en sukker-alkohol og/eller syklodekstrin, en fremgangsmåte for fremstilling av den fast dispersjonen, og en farmasøytisk sammensetning derav for anvendelse ved behandling av hyperproliferative forstyrrelser slik som kreft
CY1124852T1 (el) Φαρμακευτικες συνθεσεις 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλ) κυκλοπροπανοκαρβοξαμιδο)-3-μεθυλπυριδιν-2-υλ)βενζοϊκου οξεος και χορηγηση αυτων
HRP20190660T1 (hr) FORMULACIJA N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOHINOLIN-3-KARBOKSAMIDA U OBLIKU TABLETE ZA UPOTREBU U TRETMANU CISTIČNE FIBROZE
WO2007113851A3 (en) Novel compositions for hair disorders and process of preparation thereof
IL205872A (en) Process for the preparation of compounds 2- [4- (3- or 2-fluorobenzyloxy) benzylamino] high-purity propanamide, medicinal preparations containing them, and their use in the preparation of drugs
NZ592719A (en) PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
AR036943A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
NO20092527L (no) Prolegemidler, fremgangsmate for fremstilling og anvendelse derav
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
EP2279727A3 (en) Nanoparticulate aripiprazole formulations
IL179611A (en) History 1-Aza-bicycloalkyl, their process, their pharmaceutical preparations and their use in the preparation of drugs for the treatment of psychotic disorders
PT1915150E (pt) Utiliza??o de derivados de tienopiridona como activadores de ampk e composi??es farmac?uticas contendo os mesmos
BRPI0612188B8 (pt) preparação farmacêutica para aplicação oral, método para a produção de uma preparação farmacêutica oral, preparação de comprimido para aplicação oral, método para a produção de uma preparação de comprimido
IL187575A (en) Benzofuranyl derivatives ,pharmaceutical formulations comprising the same and use thereof in the preparation of medicaments for the treatment of 5-ht6-receptor related disorders
BR0203517A (pt) Composição farmacêutica estéril aquosa, e, método para preparar uma composição farmacêutica estéril aquosa
NO20091969L (no) N-(2-hydroksyetyl)-N-metyl-4-(quinolin-8-yl(1-(tiazol-4-ylmetyl)piperidin-4-yliden)metyl)benzamid, fremgangsmate for fremstilling av den sa vel som dens anvendelse for behandling av smerte, angst og depresjon
TW200800977A (en) A new salt
EP1778209B8 (en) Methods and compositions for oral delivery of fts
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.
NO20083213L (no) Farmasoytisk sammensetning inneholdende montelukast
AR055953A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas
NO20072743L (no) Sammensetning omfattende VLP og amyloid-betapeptid
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: REGORAFENIB; REG. NO/DATE: EU/1/13/858/001-002 20130909

Spc suppl protection certif: 2019033

Filing date: 20190805

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER HEALTHCARE LLC, US

SPCS Change of name or address of the owner of a supplementary protection certificate

Owner name: BAYER HEALTHCARE LLC, US

Spc suppl protection certif: 2019033

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: REGORAFENIB; REG. NO/DATE: EU/1/13/858/001-002 20130909

Spc suppl protection certif: 2019033

Filing date: 20190805

Extension date: 20280829